AEMD · XBRL financial data

Aethlon Medical financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (AEMD's year ends in late March)

In thousands of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Revenue	659	294	574	0	—	—
Revenue from contracts with customers	659	294	574	0	—	—
Research and development	2,072	2,341	2,745	2,520	2,212	1,912
General and administrative	2,456	3,455	4,481	3,903	3,243	2,696
Total operating expenses	8,549	10,715	12,473	12,637	9,341	7,294
Operating income (loss)	(7,890)	(10,421)	(11,899)	(12,637)	(9,341)	(7,294)
Interest income	—	—	—	—	298	157
Interest expense	—	—	—	—	10	14
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(7,887)	(10,416)	(12,030)	(12,208)	(13,388)	(7,151)
Earnings per share, basic USD per share	—	(0.71)	(0.59)	(4.86)	(8.58)	(10.61)
Earnings per share, diluted USD per share	—	(0.71)	(0.59)	(4.86)	(8.58)	(10.61)
Weighted average shares, basic thousands of shares	—	14,757	20,537	2,513	1,561	674
Weighted average shares, diluted thousands of shares	—	14,757	20,537	2,513	1,561	674

Fiscal years (AEMD's year ends in late March)

In thousands of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Cash and cash equivalents	9,862	17,072	14,533	5,442	5,501	5,026
Accounts receivable	149	128	0	—	—	—
Prepaid and other current assets	341	957	558	506	449	332
Total current assets	10,352	18,157	15,091	6,226	5,950	5,570
Property and equipment, net	161	441	1,144	1,015	676	357
Right-of-use asset	40	697	1,152	883	602	308
Total assets	10,669	19,418	17,509	8,246	7,360	6,333
Accounts payable	338	500	433	778	535	385
Total current liabilities	1,375	1,824	1,505	1,830	1,899	1,447
Lease liability, non-current	0	603	940	650	337	0
Total liabilities	1,375	2,427	2,445	2,480	2,236	1,447
Accumulated deficit	(119,913)	(130,329)	(142,359)	(154,567)	(167,955)	(175,106)
Total stockholders' equity	9,431	17,133	15,064	5,766	5,124	4,886
Total liabilities and equity	10,669	19,418	17,509	8,246	7,360	6,333
Common shares outstanding (cover page) thousands of shares	15,365	15,830	24,771	13,900	2,585	2,371

Fiscal years (AEMD's year ends in late March)

In thousands of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Net income (loss)	(7,887)	(10,416)	(12,030)	(12,208)	(13,388)	(7,151)
Stock-based compensation	779	751	1,052	1,219	415	279
Depreciation and amortization	40	124	241	359	340	324
Net cash from operating activities	(6,765)	(9,767)	(10,505)	(10,130)	(7,646)	(6,998)
Purchases of property and equipment	60	349	943	251	0	4
Net cash from investing activities	(60)	(349)	(943)	(251)	0	(4)
Proceeds from issuing common stock	—	—	8,927	1,322	3,540	6,901
Proceeds from issuing equity	7,261	17,456	8,927	—	—	—
Net cash from financing activities	7,128	17,368	8,915	1,288	7,727	6,522
Net change in cash	—	7,252	(2,534)	(9,091)	70	(474)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Aethlon Medical	4,934	not reported	(1,897)	711,136	2.6 quarters	Q1 FY27 10-QJun 30, 2026
Family Office of America	637	533	149*	30.8M	—	Q2 FY26 10-QJun 30, 2026
Glucotrack	1,124	not reported	(3,616)*	10.6M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Odyssey Health	122	not reported	(160)*	110.2M	0.8 quarters	Q4 FY26 10-KJul 31, 2026
Autonomix Medical	3,460	0	(3,544)	971,043	1.0 quarters	Q1 FY27 10-QJun 30, 2026
Sonoma Pharmaceuticals	5,338	6,406	(649)	4.8M	8.2 quarters	Q1 FY27 10-QJun 30, 2026
Adm Tronics Unlimited	223	not reported	(33)	67.6M	6.8 quarters	Q1 FY26 10-QJun 30, 2026
Nuwellis	3,922	1,969	(3,175)*	3.6M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Bone Biologics	6,088	not reported	(532)*	3.4M	9.8 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.